Recent breast cancer trends among Asian/Pacific Islander, Hispanic, and African-American women in the US: Changes by tumor subtype

Breast Cancer Research

Volumn 9, Issue 6, 2007, Pages

  Hausauer, Amelia K ^a   Keegan, Theresa HM ^a,b   Chang, Ellen T ^a,b   Clarke, Christina A ^a,b  

^a NORTHERN CALIFORNIA CANCER CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AFRICAN AMERICAN; AGE; ARTICLE; ASIAN; BREAST CANCER; CANCER INCIDENCE; CANCER REGISTRY; ETHNIC DIFFERENCE; FEMALE; HISPANIC; HORMONAL THERAPY; HUMAN; ICD-O-3; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MIDDLE AGED; PACIFIC ISLANDER; POPULATION RESEARCH; PREVALENCE; RACE DIFFERENCE; REGRESSION ANALYSIS; TREATMENT WITHDRAWAL; TUMOR VOLUME; UNITED STATES; ABORIGINE; AGED; ASIAN AMERICAN; BREAST TUMOR; CANCER INVASION; CARCINOMA IN SITU; CAUCASIAN; CHEMISTRY; ESTROGEN THERAPY; ETHNOLOGY; INCIDENCE; LUNG CARCINOMA; METHODOLOGY; NEOPLASM; PATHOLOGY; STATISTICS;

AFRICAN AMERICANS; AGED; ASIAN AMERICANS; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, LOBULAR; ESTROGEN REPLACEMENT THERAPY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASMS, HORMONE-DEPENDENT; OCEANIC ANCESTRY GROUP; PREVALENCE; RECEPTORS, ESTROGEN; RESEARCH DESIGN; SEER PROGRAM; UNITED STATES;

EID: 40349116245     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1839     Document Type: Article

References (56)

1. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA: The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007, 356: 1670-1674. 10.1056/NEJMsr070105.
2. Jemal A, Ward E, Thun MJ: Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res. 2007, 9: R28-10.1186/bcr1672.
3. Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ: Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol. 2006, 24: e49-50. 10.1200/JCO.2006.08.6504.
4. Robbins AS, Clarke CA: Regional Changes in Hormone Therapy Use and Breast Cancer Incidence, California, 2001-2004. J Clin Oncol. 2007, 25: 3437-3439. 10.1200/JCO.2007.11.4132.
5. Glass AG, Lacey JV, Carreon JD, Hoover RN: Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007, 99: 1152-1161. 10.1093/jnci/djm059.
6. Katalinic A, Rawal R: Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat. 2007 Apr 24.
7. Kerlikowske K, Miglioretti DL, Buist DS, Walker R, Carney PA: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2007, 99: 1335-1339. 10.1093/jnci/djm111.
8. Johnston M: Breast cancer drop linked to fall in use of HRT. New Zealand Herald. 20 December, 2006, [http://www.nzherald.co.nz/section/1/story.cfm?c_id=1&objectid=10416198]
9. Kliewer EV, Demers AA, Nugent ZJ: A decline in breast-cancer incidence. N Engl J Med. 2007, 357: 509-510. 10.1056/NEJMc071391. author reply 513.
10. Zahl PH, Maehlen J: A decline in breast-cancer incidence. N Engl J Med. 2007, 357: 510-511. author reply 513.
11. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002, 288: 321-333. 10.1001/jama.288.3.321.
12. Hersh AL, Stefanick ML, Stafford RS: National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004, 291: 47-53. 10.1001/jama.291.1.47.
13. Buist DS, Newton KM, Miglioretti DL, Beverly K, Connelly MT, Andrade S, Hartsfield CL, Wei F, Chan KA, Kessler L: Hormone therapy prescribing patterns in the United States. Obstet Gynecol. 2004, 104: 1042-1050.
14. Hillman JJ, Zuckerman IH, Lee E: The impact of the Women's Health Initiative on hormone replacement therapy in a Medicaid program. J Womens Health (Larchmt). 2004, 13: 986-992.
15. Wysowski DK, Governale LA: Use of menopausal hormones in the United States, 1992 through June, 2003. Pharmacoepidemiol Drug Saf. 2005, 14: 171-176. 10.1002/pds.985.
16. Kelly JP, Kaufman DW, Rosenberg L, Kelley K, Cooper SG, Mitchell AA: Use of postmenopausal hormone therapy since the Women's Health Initiative findings. Pharmacoepidemiol Drug Saf. 2005, 14: 837-842. 10.1002/pds.1103.
17. Li CI, Daling JR, Malone KE: Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol. 2003, 21: 28-34. 10.1200/JCO.2003.03.088.
18. Li CI, Anderson BO, Daling JR, Moe RE: Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA. 2003, 289: 1421-1424. 10.1001/jama.289.11.1421.
19. Li CI, Malone KE, Daling JR: Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev. 2002, 11: 601-607.
20. Anderson WF, Chu KC, Devesa SS: Distinct incidence patterns among in situ and invasive breast carcinomas, with possible etiologic implications. Breast Cancer Res Treat. 2004, 88: 149-159. 10.1007/s10549-004-1483-9.
21. Sorlie T: Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer. 2004, 40: 2667-2675. 10.1016/j.ejca.2004.08.021.
22. Signorello LB, Tarone RE: A decline in breast-cancer incidence. N Engl J Med. 2007, 357: 512-513. author reply 513.
23. Surveillance, Epidemiology, and End Results (SEER) Program SEER Stat Database: Incidence - SEER 13 Regs Public-Use, Nov 2006 Sub (1973-2004), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April based on the November 2006 submission. [http://www.seer.cancer.gov]
24. Hankey BF, Ries LA, Edwards BK: The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev. 1999, 8: 1117-1121.
25. Kim HJ, Fay MP, Feuer EJ, Midthune DN: Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000, 19: 335-351. 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z.
26. Devesa SS, Donaldson J, Fears T: Graphical presentation of trends in rates. Am J Epidemiol. 1995, 141: 300-304.
27. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K: Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med. 2004, 140: 184-188.
28. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998, 280: 605-613. 10.1001/jama.280.7.605.
29. Fitzpatrick LA, Litin SC, Bell MR: The Women's Health Initiative: a heart-to-HRT conversation. Mayo Clin Proc. 2000, 75: 559-561.
30. Wei F, Miglioretti DL, Connelly MT, Andrade SE, Newton KM, Hartsfield CL, Chan KA, Buist DS: Changes in women's use of hormones after the Women's Health Initiative estrogen and progestin trial by race, education, and income. J Natl Cancer Inst Monogr. 2005, 106-112. 10.1093/jncimonographs/lgi047. 35
31. California Health Interview Survey (CHIS) Public Use Files 2003, 2005. [http://www.chis.ucla.edu]
32. Breen N, K AC, Meissner HI, Taplin SH, Tangka FK, Tiro JA, McNeel TS: Reported drop in mammography: is this cause for concern. Cancer. 2007, 109: 2405-2409. 10.1002/cncr.22723.
33. Clarke CA, Glaser SL: Declines in breast cancer after the WHI: apparent impact of hormone therapy. Cancer Causes Control. 2007, 18: 847-852. 10.1007/s10552-007-9029-1.
34. Bartman BA, Moy E: Racial differences in estrogen use among middle-aged and older women. Womens Health Issues. 1998, 8: 32-44. 10.1016/S1049-3867(97)00093-5.
35. Brett KM, Madans JH: Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am J Epidemiol. 1997, 145: 536-545.
36. Brown AF, Perez-Stable EJ, Whitaker EE, Posner SF, Alexander M, Gathe J, Washington AE: Ethnic differences in hormone replacement prescribing patterns. J Gen Intern Med. 1999, 14: 663-669. 10.1046/j.1525-1497.1999.10118.x.
37. Brennan RM, Crespo CJ, Wactawski-Wende J: Health behaviors and other characteristics of women on hormone therapy: results from the Third National Health and Nutrition Examination Survey, 1988-1994. Menopause. 2004, 11: 536-542. 10.1097/01.GME.0000119982.77837.C4.
38. Newell DA, Markides KS, Ray LA, Freeman JL: Postmenopausal hormone replacement therapy use by older Mexican-American women. J Am Geriatr Soc. 2001, 49: 1046-1051. 10.1046/j.1532-5415.2001.49207.x.
39. Friedman-Koss D, Crespo CJ, Bellantoni MF, Andersen RE: The relationship of race/ethnicity and social class to hormone replacement therapy: results from the Third National Health and Nutrition Examination Survey 1988-1994. Menopause. 2002, 9: 264-272. 10.1097/00042192-200207000-00007.
40. Clarke CA, Purdie DM, Glaser SL: Population attributable risk of breast cancer in white women associated with immediately modifiable risk factors. BMC Cancer. 2006, 6: 170-10.1186/1471-2407-6-170.
41. Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, Daling JR: Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA. 2003, 289: 3254-3263. 10.1001/jama.289.24.3254.
42. Garcia-Closas M, Brinton LA, Lissowska J, Chatterjee N, Peplonska B, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Blair A, et al: Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer. 2006, 95: 123-129. 10.1038/sj.bjc.6603207.
43. Reeves GK, Beral V, Green J, Gathani T, Bull D: Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol. 2006, 7: 910-918. 10.1016/S1470-2045(06)70911-1.
44. Titus-Ernstoff L, Egan KM, Newcomb PA, Ding J, Trentham-Dietz A, Greenberg ER, Baron JA, Trichopoulos D, Willett WC: Early life factors in relation to breast cancer risk in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2002, 11: 207-210.
45. Newcomb PA, Titus-Ernstoff L, Egan KM, Trentham-Dietz A, Baron JA, Storer BE, Willett WC, Stampfer MJ: Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2002, 11: 593-600.
46. Beral V: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003, 362: 419-427. 10.1016/S0140-6736(03)14596-5.
47. Anderson WF, Jatoi I, Devesa SS: Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat. 2005, 90: 127-137. 10.1007/s10549-004-3777-3.
48. Behavioral Risk Factor Surveillance System (BRFSS). [http://www.cdc.gov/brfss/]
49. National Center for Health Statistics: Health, United States, 2006, With Chartbook on Trends in the Health of Americans With Special Feature on Pain. 2006, Hyattsville, MD: National Center for Health Statistics
50. Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney EA, Cousens L, White D, Taplin S, White E: Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst. 1999, 91: 2020-2028. 10.1093/jnci/91.23.2020.
51. Robbins AS, Clarke CA: Re: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2007, 99: 1815-author reply 1816-1817.
52. Surveillance, Epidemiology, and End Results (SEER) Data Access & Quality. [http://seer.cancer.gov/about/uses.html]
53. Schnitt SJ: Estrogen receptor testing of breast cancer in current clinical practice: what's the question. J Clin Oncol. 2006, 24: 1797-1799. 10.1200/JCO.2005.05.0666.
54. Clegg LX, Reichman ME, Hankey BF, Miller BA, Lin YD, Johnson NJ, Schwartz SM, Bernstein L, Chen VW, Goodman MT, et al: Quality of race, Hispanic ethnicity, and immigrant status in population-based cancer registry data: implications for health disparity studies. Cancer Causes Control. 2007, 18: 177-187. 10.1007/s10552-006-0089-4.
55. Gomez SL, Glaser SL: Misclassification of race/ethnicity in a population-based cancer registry (United States). Cancer Causes Control. 2006, 17: 771-781. 10.1007/s10552-006-0013-y.
56. Keegan TH, Gomez SL, Clarke CA, Chan JK, Glaser SL: Recent trends in breast cancer incidence among 6 Asian groups in the Greater Bay Area of Northern California. Int J Cancer. 2007, 120: 1324-1329. 10.1002/ijc.22432.